Patents by Inventor Cheuk-Kun Lau

Cheuk-Kun Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150057316
    Abstract: The present description relates to compounds of Formula I (A+ X?), a diastereoisomer, an enantiomer, or a mixture thereof, pharmaceutical composition comprising same and uses thereof for gastrointestinal endoscopic and medical imaging applications, and for the treatment of visceral pain: Where R1 and R2 are as defined herein
    Type: Application
    Filed: March 11, 2013
    Publication date: February 26, 2015
    Inventors: Jean-Francois Meunier, Cheuk Kun Lau, Daniel Guay, Gregory Bydlinski, Nadejda Spassova, Louis-David Cantin, Maxime Ranger
  • Patent number: 8895556
    Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 25, 2014
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Publication number: 20130231345
    Abstract: The invention relates to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 5, 2013
    Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Publication number: 20110152281
    Abstract: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II) and the remaining substituents are described herein; and a composition comprising the thiosemicarbazone and/or the semicarbazone. The invention also relates to a method of administration of a thiocarbazone and/or a semicarbazone; and use thereof to treat a cancer.
    Type: Application
    Filed: December 24, 2008
    Publication date: June 23, 2011
    Applicant: CRITICAL OUTCOME TECHNOLOGIES, INC.
    Inventors: Wayne R. Danter, Cheuk Kun Lau
  • Patent number: 6583126
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck Erosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Patent number: 6498151
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 24, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Patent number: 6486141
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related conditions.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Patent number: 6486142
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Patent number: 6465509
    Abstract: The invention encompasses the novel compounds of Formula I, which are useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cyclooxygenase-2 mediated diseases comprising administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: October 15, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun-Sing Li, Cheuk Kun Lau, Michel Therien, Petpiboon Prasit
  • Publication number: 20020091104
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: March 21, 2001
    Publication date: July 11, 2002
    Inventors: Chung Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Publication number: 20020058690
    Abstract: The invention encompasses the novel compounds of Formula I, which are useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Application
    Filed: June 27, 2001
    Publication date: May 16, 2002
    Inventors: Chun-Sing Li, Cheuk Kun Lau, Michel Therien, Petpiboon Prasit
  • Publication number: 20020058644
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 16, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Publication number: 20020052344
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 2, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Publication number: 20020052346
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 2, 2002
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Publication number: 20010006336
    Abstract: A battery charger for a cellular phone, having a speaker includes an ear jack connected to an ear jack of the cellular phone, for transmitting a voice signal of the cellular phone to the battery charger, a voice amplifier for amplifying the voice signal from the ear jack, and a speaker for converting the voice signal output from the voice amplifier into voice. The battery charger for a cellular phone, having a speaker further includes a communication port connected to a communication port of the cellular phone when the cellular phone is inserted(connected) to the battery charger, for mutually transmitting the voice signal, and a selector for connecting either the communication port or the ear jack with the voice amplifier.
    Type: Application
    Filed: December 28, 2000
    Publication date: July 5, 2001
    Applicant: LG Electronics Inc.
    Inventors: Sang Yong Yi, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Patent number: 6211210
    Abstract: The invention encompasses compounds of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 3, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cheuk Kun Lau, Chun-Sing Li, Cameron Black, Michel Therien, Jacques Yves Gauthier
  • Patent number: 6169188
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: January 2, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Patent number: 6020343
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: February 1, 2000
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Patent number: 5981576
    Abstract: The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Patent number: 5677318
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: October 14, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Cheuk Kun Lau